特朗普拟推“全球最低价”药改令 美药价或降八成

Group 1 - The core point of the news is that President Trump plans to sign an executive order aimed at reducing prescription drug costs in the U.S., ensuring that Americans pay no more than the lowest prices in other countries, potentially leading to a price drop of 30% to 80% [1][2] - The policy is referred to as the "most favored nation policy," which aims to align U.S. drug prices with those of the lowest-paying countries, significantly lowering healthcare costs [1][2] - Following the announcement, stock prices of Asian pharmaceutical companies fell, with notable declines such as a 7.2% drop for Chugai Pharmaceutical in Japan and over 3% declines for several South Korean firms [1] Group 2 - The U.S. currently has the highest drug prices globally, which has driven innovation and growth in the pharmaceutical industry; however, reforming this system may significantly reduce revenues and hinder the development of breakthrough therapies [2] - The executive order lacks detailed operational guidelines, including whether it will apply only to government programs like Medicare or to specific drugs, raising questions about its implementation [2][3] - During Trump's first term, a pilot program was proposed to align Medicare drug prices with those in lower-cost countries, but it was blocked in federal court due to procedural issues, and the Biden administration did not appeal the ruling [3]